About: Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 January 2006

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 2006 (uk) article scientifique (publié 2006) (fr) im Jahr 2006 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xineru de 2006 (ast) artikull shkencor i botuar më 01 janar 2006 (sq) scientific article published on 01 January 2006 (en)
publication date	wds:Q82150860-7B318C94-5694-4322-8EA1-2A73F8E0B2DD
publication date	2006-01-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q82150860-101E5C21-3B96-49C8-B74A-386635D3FC08 wds:Q82150860-2EC583AD-8C19-452D-B029-3FDFBDA3460C wds:Q82150860-3A8FA5DE-D66E-4878-8523-4CDD68082195 wds:Q82150860-40AB20EC-A52A-4E93-9BAE-CEDBAAF7CC21 wds:Q82150860-4DAEBD50-8D72-49BF-B55D-3485038F93E9 wds:Q82150860-58487B71-8216-40BC-B801-092908109E92 wds:Q82150860-59356E78-AE51-49BE-BB39-308144B47FA3 wds:Q82150860-664E1187-8129-4515-A916-7DCEA55E0467 wds:Q82150860-66560E63-6800-433D-B65B-D71CA7E7FAA1 wds:Q82150860-ACD3789E-97B4-44E5-9C1C-77958734A4F9 wds:Q82150860-C4510D36-D78F-47D8-A3D2-643978620A9D wds:Q82150860-C4E46787-B688-431E-B3D4-B24D2BFCF37B wds:Q82150860-E0F83635-48C5-4E22-A1C6-75DCEB280FC5 wds:Q82150860-EF7D6070-9591-4BC3-8CE4-62760F747800 wds:Q82150860-F3EC9646-9D20-4CA3-A3F8-AC973C9BE1A4 wds:Q82150860-FD3A0326-A7AD-4043-9597-105B3FAA3C4A wds:Q82150860-FD8A586D-0560-40C6-AD57-AFD02F4BB78D wds:Q82150860-FDCA852D-0F48-4DDC-A756-CC9A18354DCE wds:Q82150860-FF07490C-85D4-4724-A5B9-3AB7F9488A7C
cites work	Transurethral resection of superficial bladder cancer: technically safe, oncologically anything but perfect Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial BCG immunotherapy of bladder cancer: 20 years on. Contemporary management of stage T1 transitional cell carcinoma of the bladder Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group
author name string	wds:Q82150860-46448B88-648A-4AB0-8473-3E469E8F709C wds:Q82150860-466B0030-2CE6-4D38-AE7F-AA4014E6C9E2 wds:Q82150860-935CDA25-2E2A-4FC6-9693-4B7307FF2F8F wds:Q82150860-94B72F24-BAF4-41FD-B1E8-CD6D8C33A4E0 wds:Q82150860-9CBFCA23-F6F6-4FAD-A14D-5D6FF216E6DB wds:Q82150860-AE247752-DC93-42D3-B79B-B5ED1B6B594F wds:Q82150860-B057F84B-28DD-4A03-AEE7-45AABFAEE14B wds:Q82150860-C23A5703-35A9-48D3-8019-C926D59C3B9D wds:Q82150860-F324BD3C-1738-4016-B73E-0EA903F151E5
author name string	Savino M Di Stasi Giuseppe Vespasiani Antonella Giannantoni Francesco Attisani Robert L Stephen Germano Zampa Andrea De Carolis Arcangelo Giurioli Luigi Storti
rdfs:label	Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (en) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (nl) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (sq)
skos:prefLabel	Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (en) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (nl) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (sq)
name	Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (en) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (nl) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (sq)
author	wds:Q82150860-10CA7DBB-26E5-4BF9-A49B-AD07585D4BD8 wds:Q82150860-8C2C307D-9C3E-4853-A9FE-DBB26F991D7F
author	Marco Valenti Giovanni Capelli
title	wds:Q82150860-CE97FC4C-47BA-4F44-AE90-41C9765ABCC6
title	Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial (en)
page(s)	wds:Q82150860-EF271D04-7E25-460C-9139-98C7899523FB
page(s)	43-51
instance of	wds:Q82150860-670120B4-868C-49DF-B877-3FCF89A3DF54
instance of	scholarly article
main subject	wds:Q82150860-CA6DD452-A455-4EF8-96BD-A1B2DDDBD601 wds:Q82150860-FA708549-5480-4DC1-B786-E26AB204141A
main subject	bladder cancer randomized controlled trial
PubMed ID	wds:Q82150860-053C2CEA-21B8-44EB-B7EA-6C70CE053DAA
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/16389183
PubMed ID	16389183
published in	wds:Q82150860-10D0FE0F-03CA-4337-9CB3-3641E8A6E8EE
published in	Lancet Oncology Commission
issue	wds:Q82150860-AE2325EF-2692-4DC1-B1EF-CA8D6190FEA8
volume	wds:Q82150860-54509820-48A1-4E4E-94F8-D46F5CCF2960
issue	1
volume	7
DOI	wds:Q82150860-ED034B08-2FCA-4AD9-99EC-4867047AE2CF
DOI	http://dx.doi.org/10.1016/S1470-2045(05)70472-1

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software